You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Developing Active Stimulation and Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative Care

    SBC: PASCALL Systems, Incorporated            Topic: 106

    Project Summary Surgery and acute post-operative pain are major contributors to persistent pain, chronic pain, and opioid dependence. Currently, there are no products on the market in the United States that can be used to monitor surgical nociception. Existing products use indicators that are susceptible to intraoperative influences such as blood loss, anesthetic drugs and antihypertensives. This ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Controlled Gradient Release of Biologics: Enhanced Nerve Conduit for Long‐Gap Injury Repair

    SBC: Pioneer Neurotech Inc.            Topic: 106

    Project Summary / Abstract Nerve injuries arising from trauma, disease, or as a surgical necessity, lead most often to permanent loss of some or all functions mediated by the injured nerves. 50,000 peripheral nerve procedures are performed every year in the US, and 300,000 across Europe. After complete transection of a nerve, the optimal clinical procedure for nerve repair remains the surgical end ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Despite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a virtual reality guided acupuncture imagery treatment for Chronic low back pain

    SBC: MASSACHUSETTS NEURO TECHNOLOGY, INC.            Topic: NCCIH

    Project Summary Low back pain (LBP) is one of the most common reasons for physician visits in the USA. A substantial number of chronic LBP (cLBP) patients do not adequately respond to current treatment options. Thus, the development of new treatments for cLBP is urgently needed. The use of imagery to treat illness, including chronic pain, is one of the oldest medical practices. Although still unde ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B

    SBC: NECTAGEN INC            Topic: NIAID

    Infection with the bacterium C. difficile is the most common and increasingly prevalent cause of diarrhea. In the United States, cases of C. difficile infection (CDI) are estimated to number 500,000 annually and to result in an estimated 15,000 to 30,000 deaths. The cost of these cases is thought to exceed $4.8 billion annually. CDI continues to cause discomfort, serious illness and sometimes deat ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration

    SBC: CRIMSON BIOPHARM INC            Topic: NCI

    PROJECT SUMMARY The epidermal growth factor receptor (EGFR) gene is mutated and/or amplified in majority of primary glioblastoma (GBM). While EGFR-mutant GBM cancer cells are dependent on EGFR signaling for survival, numerous small molecule EGFR tyrosine kinase inhibitors (TKIs) have failed to show efficacy in this disease. There are two main reasons for these failures: i) Many of these EGFR-TKIs ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Preclinical evaluation of SERCA2 allosteric activators for pancreatic β-cell protection in diabetes.

    SBC: NEURODON, LLC            Topic: NIDDK

    The overall goal of this collaborative project between Neurodon and Indiana University School of Medicine is the development of compounds that will offer disease-modifying treatments for type 1 (T1D) and type 2 diabetes (T2D) mellitus, a sorely unmet need. In this initial STTR project, we will use our expertise in medicinal chemistry, cell biology, and diabetes pathophysiology to functionally test ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. 3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring

    SBC: Axioforce LLC            Topic: NIBIB

    PROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Developing of a computer-based multimodal mind and body approach for mild cognitive decline

    SBC: BRAIN THRIVE TECHNOLOGY LLC            Topic: NIA

    Summary Mild cognitive impairment (MCI) represents an intermediate state between normal aging and the diagnosis of clinically probable very early Alzheimer's disease (AD). Since MCI manifests before the onset of AD, it may be the optimal stage in which to intervene with preventative therapies for AD and age-related dementia before progressive neurological loss and irreversible cognitive impairment ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government